Article

seattletimes.com on 2023-04-27 14:44

Merck has strong quarter even as COVID-19 treatment tumble

Merck beat first-quarter expectations and hiked its 2023 forecast even as sales plunged for its COVID-19 treatment and a strong dollar hurt revenue.

TOM MURPHY

Related news

Merck has strong fourth quarter as COVID-19 treatment debuts Seattle Times
New Jersey , Kenilworth , Wall Street
Merck posts strong first-quarter profit, but revenue light apnews.com
New Jersey , Wall Street , Japan , Kenilworth
COVID-19 treatment, Keytruda boost Merck in 1Q Seattle Times
New Jersey , Kenilworth , China
HA Strong 2Q for Merck, Outlook Mixed hamodia.com
United Kingdom , New Jersey , Wall Street
MEarnings outlook is getting even worse as first-quarter expectations tumble marketwatch.com
BMicrosoft Stock Rises on Another Strong Quarter. Even Windows Is Doing Well.barrons.com
Wall Street
After another strong quarter, CVS raises outlook for 2022 ocregister.com
Rhode Island , Woonsocket , Wall Street , Florida
Pfizer, Merck, Regeneron: Covid Treatment Stocks Back In Focus As Infections Soar Forbes
South Africa , Italy , Japan , United Kingdom , Puers
LEye Allergy Treatment Market Size, Key Opportunities, Strategic Assessment, Strong Revenue | Oprating Vendors: ALLERGAN, Johnson & Johnson Vision Care, Merck, Novartis, Pfizer, Regeneron Pharmaceut…liverpoolstudentmedia.com
Africa , Middle East , Mexico , Brazil , Latin America
Merck 4Q powered by cancer treatment sales bradenton.com
New Jersey , Kenilworth
Merck profits reach $687M in second quarter The Salt Lake Tribune
Wall Street , Kenilworth
FMerck wins approval for skin cancer treatment ft.com
AA strong 2Q for Merck, outlook mixed apnewsarchive.com
New Jersey , Wall Street , Kenilworth
Ford’s 1st quarter net takes 24% tumble nwaonline.com
Wall Street , Shanghai
Merck shares soar along with its first quarter profit Seattle Times
New Jersey , China , Wall Street , Kenilworth